Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Adjusted annual direct and indirect costs

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Adjusted mean annual costs (€)
 Direct costs Total Outpatient costs Inpatient costs Medication costs Other costs
 % zero costs 0% 0% 62% 0% 56%
 Group  
  A 7460 [7026 – 7924] 937 [902 – 973] 3586 [3201 – 4010] 2522 [2381 – 2663] 566 [513 – 628]
  B1 7117 [6029 – 8392] 2570 [2256 – 2866] 1715 [740 – 3076] 2144 [1903 – 2409] 777 [529 – 1049]
  B2 6099 [4288 – 8256] 1061 [763 – 1414] 2338 [561 – 5288] 1805 [1388 – 2261] 876 [319 – 1659]
Adjusted mean annual costs (€)
 Indirect costs Human capital approach Friction costs approach
 % zero costs   26%   72%  
 Group  
  A   19,583 [18,451 – 20,803] 981 [839 – 1138]
  B1   18,813 [13,632 – 24,716] 1276 [608 – 2181]
  B2   16,171 [6194 – 28,316] 1866 [633 – 3764]
  1. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT
  2. Significant estimates on a level of p < 0.05 are printed bold. Indirect costs only include participants < 65 years of age
  3. Totals direct costs and medication costs do not include AT costs of approximately €72,000